

0900 GMT
06 May 2024
Cheadle, Stockport, UK

Stockport based, Seda Pharmaceutical Development Services wins King's Award for Enterprise 2024

Seda is one of only 252 organisations nationally to be recognised with a prestigious King's Award for Enterprise

Cheadle, Stockport: Announced today, 6th May 2024, Seda has been recognised for its excellence in international trade, winning the King's Award for Outstanding Short-Term Growth in overseas sales.

"We are absolutely delighted that Seda has been recognised with this most prestigious award" said Seda CEO, Dr Paul Stott

"It is a testament to the exceptional service underpinned by scientific excellence that our team consistently delivers, which has been the key driver of our recent growth.

Global partnerships now account for more than half of our business and based on our increasing global reach and enhanced service offering, we expect that share to grow significantly over the coming years."

Seda supports biotech clients in the design, development and market approval of novel medicinal products in a wide range of therapeutic areas.

The company has made significant investment in premises, equipment and in the expansion and development of the team to enhance its offering and meet client demand. In late 2024, it will be opening a neighbouring state-of-the art manufacturing facility to supply products for evaluation in clinical trials.

The King's Award is the latest of several awarded to Seda for its commercial and technical achievements.

-Ends-

For more information:

Paula Goddard
Paula.goddard@sedapds.com

Product

www.Sedapds.com